307 related articles for article (PubMed ID: 30935213)
1. Budget impact of niraparib as maintenance treatment in recurrent ovarian cancer following platinum-based chemotherapy.
Neeser K; O'Neil WM; Stern L; Harrow B; Travers K
J Comp Eff Res; 2019 Jun; 8(8):577-587. PubMed ID: 30935213
[No Abstract] [Full Text] [Related]
2. Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.
Wu L; Zhong L
J Med Econ; 2019 Feb; 22(2):187-195. PubMed ID: 30522378
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer.
Zhong L; Tran AT; Tomasino T; Nugent E; Smith JA
J Manag Care Spec Pharm; 2018 Dec; 24(12):1219-1228. PubMed ID: 30479195
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma.
Wolford JE; Bai J; Moore KN; Kristeleit R; Monk BJ; Tewari KS
Gynecol Oncol; 2020 May; 157(2):500-507. PubMed ID: 32173049
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States.
Penn CA; Wong MS; Walsh CS
JAMA Netw Open; 2020 Dec; 3(12):e2028620. PubMed ID: 33295974
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States.
Guy H; Walder L; Fisher M
Pharmacoeconomics; 2019 Mar; 37(3):391-405. PubMed ID: 30478649
[TBL] [Abstract][Full Text] [Related]
7. Budget impact analysis of niraparib for first-line maintenance therapy in advanced ovarian cancer from a US payer perspective.
Liu J; Hawkes C; Walder L; Spalding C; Travers K; Maiese EM; Hurteau J
J Manag Care Spec Pharm; 2021 Oct; 27(10):1377-1387. PubMed ID: 34595950
[No Abstract] [Full Text] [Related]
8. Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice.
Eakin CM; Ewongwo A; Pendleton L; Monk BJ; Chase DM
Gynecol Oncol; 2020 Oct; 159(1):112-117. PubMed ID: 32811682
[TBL] [Abstract][Full Text] [Related]
9. Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
Kurnit KC; Coleman RL; Westin SN
Curr Treat Options Oncol; 2018 Nov; 19(12):1. PubMed ID: 30535808
[TBL] [Abstract][Full Text] [Related]
10. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
[TBL] [Abstract][Full Text] [Related]
11. Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis.
Barrington DA; Tubbs C; Smith HJ; Straughn JM; Senter L; Cohn DE
Int J Gynecol Cancer; 2020 Oct; 30(10):1569-1575. PubMed ID: 32753559
[TBL] [Abstract][Full Text] [Related]
12. [PARP inhibitors in first-line of ovarian cancers].
Rodrigues M
Bull Cancer; 2020 Jan; 107(1):4-5. PubMed ID: 31928735
[No Abstract] [Full Text] [Related]
13. Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
Wang L; Wang Q; Xu Y; Cui M; Han L
Curr Drug Targets; 2020; 21(2):167-178. PubMed ID: 31553293
[TBL] [Abstract][Full Text] [Related]
14. Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.
Onstad M; Coleman RL; Westin SN
Drugs; 2020 Oct; 80(15):1525-1535. PubMed ID: 32852746
[TBL] [Abstract][Full Text] [Related]
15. [New drug approval: Olaparib and niraparib - first line in ovarian cancer].
Delaye M; Rodrigues M
Bull Cancer; 2021 Apr; 108(4):350-351. PubMed ID: 33641880
[No Abstract] [Full Text] [Related]
16. Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Kerliu L; Myruski S; Bhatti A; Soni P; Petrosius P; Pervanas HC; Horton ER
Ann Pharmacother; 2020 Oct; 54(10):1010-1015. PubMed ID: 32172572
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.
Armeni P; Borsoi L; Fornaro G; Jommi C; Colombo N; Costa F
Clin Ther; 2020 Jul; 42(7):1192-1209.e12. PubMed ID: 32591103
[TBL] [Abstract][Full Text] [Related]
18. Latest clinical evidence of maintenance therapy in ovarian cancer.
Walsh CS
Curr Opin Obstet Gynecol; 2020 Feb; 32(1):15-21. PubMed ID: 31833941
[TBL] [Abstract][Full Text] [Related]
19. Indirect comparison of three PARP inhibitors (olaparib, niraparib, and rucaparib) as maintenance treatment in ovarian carcinoma patients responding to platinum therapy.
Mengato D; Cancanelli L; Di Spazio L; Rivano M; Chiumente M; Messori A
Int J Clin Pharmacol Ther; 2022 Aug; 60(8):370-372. PubMed ID: 35652551
[No Abstract] [Full Text] [Related]
20. Niraparib: First Global Approval.
Scott LJ
Drugs; 2017 Jun; 77(9):1029-1034. PubMed ID: 28474297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]